公开(公告)号：WO2011145909A3

公开(公告)日：2012-03-29

申请号：PCT/KR2011003735

申请日：2011-05-20

Applicant: BIOCARE CO LTD ,  NEWTREE CO LTD ,  HWANG JAE-KWAN ,  KIM DO UN

Inventor： HWANG JAE-KWAN ,  KIM DO UN

IPC: A61K31/05 ,  A61K36/906 ,  A61P21/00 ,  A61P43/00

CPC classification number: A61K36/906 ,  A23L33/105 ,  A61K31/12 ,  A61K36/00

Abstract: The present invention relates to the novel use of panduratin derivatives or an extract of Boesenbergia pandurata for promoting muscle mass growth, fighting fatigue, and enhancing exercise performance capability. More particularly, the present invention relates to a composition for enhancing exercise performance capability, promoting muscle mass growth, and fighting fatigue, which comprises panduratin derivatives or salts thereof, or an extract of Boesenbergia pandurata, as active ingredients, and which promotes muscle mass growth and recovery from fatigue to improve mobility. The present invention also relates to a method for improving exercise performance capability, promoting muscle mass growth, and fighting fatigue, which involves injecting panduratin derivatives or salts thereof, or an extract of Boesenbergia pandurata, into an individual requiring same. The panduratin derivatives or the extract of Boesenbergia pandurata of the present invention can be used safely with no adverse effects, and increases the expression of PPAR d in the muscles, thus exhibiting excellent effects in promoting muscle mass growth, recovery from fatigue, and an enhancement in exercise performance capability such as an enhancement in mobility.

Abstract translation: 本发明涉及潘多蛋白衍生物或泛黄柏提取物的新用途，用于促进肌肉生长，抗疲劳，提高运动能力。 更具体地，本发明涉及一种用于增强运动性能能力，促进肌肉量增长和抗疲劳的组合物，其包含潘多汀衍生物或其盐，或作为活性成分的Boesenbergia pandurata的提取物，并且其促进肌肉质量生长 并从疲劳中恢复，提高流动性。 本发明还涉及一种用于提高运动能力，促进肌肉量增长和抗疲劳的方法，其包括将潘多蛋白衍生物或其盐，或Boesenbergia pandurata的提取物注射到需要相同的个体中。 可以安全地使用本发明的潘氏白藜芦素衍生物或提取物，没有副作用，并且增加肌肉中PPAR d的表达，因此在促进肌肉量生长，疲劳恢复和增强方面表现出优异的效果 在运动表现能力，如增加流动性。

公开(公告)号：WO2012102555A2

公开(公告)日：2012-08-02

申请号：PCT/KR2012000611

申请日：2012-01-26

Applicant: KIM JONG-KI ,  NEWTREE CO LTD

Inventor： KIM JONG-KI

IPC: A61K31/737 ,  A61K36/37 ,  A61P7/02 ,  A61P9/00

CPC classification number: A61K31/737

Abstract: To study different types of thrombolytic agents, both thrombolysis and stimulation of fucoidan were studied in a mouse model of ferric chloride-induced arterial thrombosis and were compared with those of a heparin and tissue plasminogen activator (t-PA). Thrombosis was induced by applying a filter paper saturated with 5% FeCl3 to the left carotid artery. 20 minutes after complete occlusion, several test preparations including a fucoidan source from Undaria pinnatifida sporophylls were intravenously injected to each mouse group by various dosages of 10-200 mg/kg-1. To study the stimulation effect of fucoidan with respect to t-PA, fucoidan added in a predetermined amount of t-PA was injected by a dose of 1-10 mg/kg. Then, the time to reperfusion was measured. As a result, an occluded aorta was dose-dependently reperfused, and the reperfusion was observed at 37.5±12.4 minutes after the administration of 100 mg/kg-1 of unfractionated fucoidan. The time to reperfusion was retarded to 55.0±8.0 minutes when a large amount of fucoidan such as 1 g/kg-1 was administered to a mouse provided with low molecular weight fucoidan (LMWF). Reperfusion occurred at 16.67 minutes after administration in a mouse of a control group provided with 20 mg/kg-1 of t-PA. On the contrary, reperfusion was not observed in an occluded mouse provided with heparin (p

Abstract translation: 研究不同类型的溶栓剂，在氯化铁诱导的动脉血栓形成的小鼠模型中研究溶栓和刺激岩藻依聚糖，并与肝素和组织纤溶酶原激活物（t-PA）进行比较。 通过将饱和5％FeCl 3的滤纸施加到左颈动脉来诱导血栓形成。 完全闭塞20分钟后，通过各种剂量的10-200 mg / kg-1静脉滴注几种测试制剂，其中包括来自Undaria pinnatifida sponophylls的岩藻依聚糖源。 为了研究岩藻依聚糖相对于t-PA的刺激作用，以1-10mg / kg的剂量注射添加在预定量的t-PA中的岩藻依聚糖。 然后，测量再灌注的时间。 结果，闭塞性主动脉被剂量依赖性再灌注，并且在给予100mg / kg-1未分级岩藻依聚糖后37.5±12.4分钟观察到再灌注。 当向具有低分子量岩藻依聚糖（LMWF）的小鼠施用大量的岩藻依聚糖如1g / kg-1时，再灌注时间延迟至55.0±8.0分钟。 在给予20mg / kg-1的t-PA的对照组的小鼠中，在16.67分钟后发生再灌注。 相反，在肝素闭塞的小鼠中没有观察到再灌注（p <0.01）。 如果在规定量的t-PA中添加了最少量的岩藻依聚糖，则在注射后17.2分钟就没有再灌注回收闭塞动脉。 所有数据显示，与肝素不同，岩藻依聚糖可用作血栓形成模型中t-PA溶栓活化的溶栓剂和兴奋剂。

公开(公告)号：WO2016190682A3

公开(公告)日：2017-01-19

申请号：PCT/KR2016005585

申请日：2016-05-26

Applicant: NEWTREE CO LTD

Inventor： HWANG JAE-KWAN ,  KIM MI-BO ,  KIM CHANGHEE ,  KIM DOUN ,  CHUNG HEECHUL

IPC: A61K31/352 ,  A61K36/605

CPC classification number: A61K31/352 ,  A61K36/605

Abstract: The present invention relates to a composition for preventing and treating muscle diseases or improving muscular function, containing, as an active ingredient, at least one selected from the group consisting of morusin, kuwanon G, and a Mori Cortex Radicis extract. The Mori Cortex Radicis extract, morusin, or kuwanon G, according to the present invention, has an effect of remarkably enhancing muscular function by increasing the expression of p-mTOR protein involved in muscular protein synthesis, inhibiting the expression of mRNAs of MuRF-1 and atrogin-1 involved in muscular protein degradation, and increasing the expression of mRNAs of MyoD and myogenin involved in muscle differentiation. In addition, the present invention is a natural product so as to be used safely without side effects, thereby being usable in drugs, food, or cosmetics.

Abstract translation: 本发明涉及一种用于预防和治疗肌肉疾病或改善肌肉功能的组合物，其含有选自由morusin，kuwanon G和Mori Cortex Radicis提取物组成的组中的至少一种作为有效成分。 根据本发明的Mori Cortex Radicis提取物，morusin或kuwanon G具有通过增加参与肌肉蛋白质合成的p-mTOR蛋白的表达来显着增强肌肉功能的作用，抑制MuRF-1的mRNA的表达 和atrogin-1参与肌肉蛋白降解，并增加MyoD和myogenin mRNAs在肌肉分化中的表达。 此外，本发明是天然产物，其安全使用而没有副作用，因此可用于药物，食品或化妆品。

公开(公告)号：WO2010041908A2

公开(公告)日：2010-04-15

申请号：PCT/KR2009005804

申请日：2009-10-09

Applicant: NEWTREE CO LTD ,  HWANG JAE-KWAN ,  KIM DO UN

Inventor： HWANG JAE-KWAN

IPC: A61K31/05

CPC classification number: A23C9/152 ,  A23L2/02 ,  A23L2/52 ,  A23L13/67 ,  A23L23/00 ,  A23L33/105 ,  A23L33/30 ,  A61K31/121 ,  A61K36/906

Abstract: The present invention relates to a novel use of panduratin derivative or Boesenbergia pandurata extract. More specifically, the present invention relates to: a composition containing panduratin derivative or Boesenbergia pandurata extract denoted by chemical formulas 1 to 3 as an active ingredient for preventing and treating/relieving metabolic disease; a method for treating metabolic disease characterized by administering effective amount of panduratin derivative or Boesenbergia pandurata extract to a needed individual; a use of the panduratin derivative or Boesenbergia pandurata extract to manufacture a formulation for preventing and treating/relieving metabolic diseases. The metabolic disease is selected from the group consisting of obesity, hyperlipidemia, hypercholesterolemia, and diabetes. The present invention provides a novel use of the panduratin derivative or Boesenbergia pandurata extract. The panduratin derivative or Boesenbergia pandurata extract of the present invention has an effect on metabolic disease such as obesity, hyperlipidemia, hypercholesterolemia, and diabetes by reducing a factor relating to the metabolic disease such as weight, body fat, or lipid content. Thus, the present invention provides a novel means which is safely used as a natural substance without side effects and is effective in preventing and treating/relieving metabolic diseases through weight loss and body fat reduction.

Abstract translation: 本发明涉及一种潘多汀衍生物或潘氏白僵菌提取物的新用途。 更具体地说，本发明涉及以化学式1〜3表示的作为预防和治疗/缓解代谢性疾病的活性成分的潘多汀衍生物或潘氏石斛提取物的组合物， 一种治疗代谢性疾病的方法，其特征在于向需要的个体施用有效量的潘多汀衍生物或Boesenbergia pandurata提取物; 使用潘多汀衍生物或Boesenbergia pandurata提取物制备用于预防和治疗/缓解代谢性疾病的制剂。 代谢疾病选自肥胖症，高脂血症，高胆固醇血症和糖尿病。 本发明提供了潘多汀衍生物或潘氏白僵菌提取物的新用途。 本发明的潘多汀衍生物或潘氏白僵菌提取物通过减少与代谢疾病如体重，体脂肪或脂质含量有关的因素，对代谢疾病如肥胖症，高脂血症，高胆固醇血症和糖尿病具有影响。 因此，本发明提供了一种新颖的方法，其被安全地用作天然物质而没有副作用，并且通过减肥和减少体重有助于预防和治疗/减轻代谢疾病。